1. The pathogenesis of Barrett’s esophagus: A process in Continuum or discontinuum

   • Rebecca C. Fitzgerald
   • Michael J. G. Farthing

   OriginalPaper Pages: 421 - 424

2. Web alert

   News Pages: 425 - 426

3. Literature alert

   Abstract Pages: 427 - 429

4. Update on inflammatory bowel disease genetics

   • Judy Cho

   OriginalPaper Pages: 434 - 439

5. Clinical pharmacology of inflammatory bowel disease therapies

   • William J. Sandborn
   • William A. Faubion

   OriginalPaper Pages: 440 - 445

6. Medical therapies for ulcerative colitis and crohn’s disease

   • Filip J. Baert
   • Paul J. Rutgeerts

   OriginalPaper Pages: 446 - 450

7. Neoplastic and other complications of inflammatory bowel disease

   • Charles N. Bernstein

   OriginalPaper Pages: 451 - 459

8. Maintenance therapies for crohn’s disease: Steroid dependence and delaying postoperative recurrence

   • Stephen B. Hanauer

   Clinical Trials Report Pages: 460 - 460

9. Clinical trials report

   • Wilfred M. Weinstein

   BriefCommunication Pages: 463 - 464

10. Dysplasia east and west

    • Robert M. Genta

    OriginalPaper Pages: 465 - 470

11. What have we learned from recent dyspepsia trials?

    • Joshua J. Ofman

    OriginalPaper Pages: 471 - 477

12. Adjuvant therapy for gastric cancer: A reality at last

    • J. Randolph Hecht

    OriginalPaper Pages: 478 - 481

13. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole

    • Alan B. R. Thomson

    OriginalPaper Pages: 482 - 493

14. A critical review of the effect of Helicobacter pylori eradication on gastric MALT lymphoma

    • Andrew C. Wotherspoon

    OriginalPaper Pages: 494 - 498